BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC
The China Center for Drug Evaluation (CDE) website has indicated that the market approval filing...
Company
Beijing Tinavi Medical Technologies to Form Radiotherapy Equipment JV with IM INNO and Celestial Oncology
Beijing Tinavi Medical Technologies Co., Ltd (SHA: 688277) has announced its intention to establish a...
Pfizer’s RSV Vaccine Demonstrates Durable Efficacy with Abrysvo Phase III Results
Pfizer Inc. (NYSE: PFE) last week reported the outcomes of a Phase III trial for...
Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE
The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group)...
J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions
The US Food and Drug Administration (FDA) has granted Johnson & Johnson (J&J; NYSE: JNJ)...
Astellas Launches Late-Stage Trial in Japan for Nonhormonal Menopause Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, last week initiated a late-stage...
Maruho Expands into China with New Wholly Owned Subsidiary in Beijing
Japan-based Maruho has announced the establishment of a wholly owned subsidiary in Beijing, marking its...
Sino-US Laekna’s LAE102 Clinical Trial Filing Accepted for Review in Obesity and Metabolic Disorders
Sino-US Laekna (HKG: 2105) has announced that its clinical trial application for LAE102, an antibody...
Haihe Pharmaceuticals Licenses Glumetinib to Taiho for Exclusive Development in Japan and Asia
Shanghai Haihe Pharmaceutical Co., Ltd has entered into a licensing agreement with Taiho Pharmaceutical Co.,...
CANbridge Pharmaceuticals Partners with Peking Union Medical College to Advance Rare Disease Research
CANbridge Pharmaceuticals Inc. (HKG: 1228), a specialist in rare diseases based in China, has announced...
Fosun Pharmaceutical Secures NMPA Approval for Phase II Study of FCN-338 and FCN-647 in Chronic Lymphocytic Leukemia
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Shanghai Pharmaceuticals’ MediTrust Health Teams Up with Eisai to Enhance Alzheimer’s Prevention and Treatment
Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607, HKG: 2607)’s subsidiary MediTrust Health, which specializes in...
Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...
Jiangsu Hengrui Receives NMPA Approval for HRS-1167 Clinical Trials in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276) has secured clinical trial approval from the National...
Innovent Biologics Launches Phase I Study for IBI3002, a Bispecific Antibody Targeting Asthma
Innovent Biologics, Inc. (HKG: 1801), based in China, has announced the initiation of its Phase...
CDE Grants Priority Review to Jiu An’s Adrenaline and AnHeart’s Taletrectinib; Two Others Earn Breakthrough Therapy Designation
The Center for Drug Evaluation (CDE) has announced that Jiu An Pharmaceutical’s adrenaline and AnHeart...
Sandoz Agrees to $265 Million Settlement in U.S. Generic Drug Antitrust Case
Sandoz (SIX: SDZ), the Swiss-based pharmaceutical company, announced this week that its U.S. subsidiaries have...
Huadong Medicine’s MaiLi Extreme Achieves Clinical Study Milestone for Chin Retraction Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that a Chinese clinical study for...
ARSMO Plastic Aesthetic Hospital Introduces Liquid PCL Implant GOURI in Hainan
ARSMO Plastic Aesthetic Hospital Holding Co., Ltd. has announced the inaugural application of GOURI, a...
CARsgen Therapeutics’ BCMA-targeted CAR-T Cell Therapy Approved by China’s NMPA
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a specialist in chimeric antigen receptor (CAR)-T cell therapies...